An update from Fulcrum Therapeutics (FULC) is now available.
At Fulcrum’s 2024 annual meeting, stockholders elected James Collins, James Geraghty, and Alex Sapir as class II directors for a three-year term. Additionally, Ernst & Young LLP was ratified as the independent accounting firm for the year. The directors were chosen by a significant majority, with Collins and Sapir receiving particularly strong support, and the accounting firm’s selection was overwhelmingly approved, reflecting stockholder confidence in the company’s governance and financial oversight.
Learn more about FULC stock on TipRanks’ Stock Analysis page.
